Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Gordon v. Vanda Pharmaceuticals Inc. et al
Case Number:
1:19-cv-01108
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
September 16, 2022
Vanda Pharma Investors' $11.5M Deal Gets Judge's Initial OK
A Brooklyn federal judge has given an initial nod to the proposed $11.5 million settlement of investors' claims that Vanda Pharmaceuticals Inc. hid from the public that it was illegally marketing its drugs for off-label use.
-
March 10, 2021
Vanda Pharma Can't Nix Investors' Off-Label Fraud Suit
A New York federal judge declined Wednesday to allow Vanda Pharmaceuticals Inc. or its CEO to slip a proposed securities class action alleging the company misled investors by aggressively marketing drugs for nonapproved uses, but he did allow three other Vanda executives out of the case.
-
February 25, 2019
Vanda Hid Off-Label Fraud Scheme From Investors, Suit Says
Disgruntled Vanda Pharmaceuticals Inc. shareholders filed a proposed securities class action against the company Monday that alleges Vanda executives misled investors for years by aggressively marketing drugs for nonapproved uses to juice profits.